Sequencing in 24 Hours: February 2025 Edition
Dear subscribers,
Welcome to the February 2025 Edition! Two decades ago, people invested over a decade and more than $3 billion to sequence a single human genome. With continuous advancements in technology and equipment, MGI has successfully reduced the cost of genomic sequencing to under $100. Now, we are poised to take another significant leap forward by achieving sequencing within just 24 hours. This remarkable progress not only underscores the rapid innovation in the field of genomics but also opens up new possibilities for research and personalized medicine.
Explore other highlights throughout February:
Complete sequencing in 24 Hours with DNBSEQ-T1+
On February 24, MGI launched its latest high-performance sequencing solutions at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting through its U.S. subsidiary, Complete Genomics.
The DNBSEQ-T1+ stands out as one of the fastest T-level benchtop sequencers globally, powered by MGI's proprietary DNBSEQ? sequencing technology. This advanced sequencer can perform a paired-end 150 sequencing workflow in just 24 hours with Q40 accuracy. With three flow cell formats, two to four addressable lanes on each flow cell, and the capability for dual independent flow cell operation, the DNBSEQ-T1+ increases data output while reducing turnaround times and enhancing laboratory efficiency and flexibility.
The DNBSEQ-T1+ elevates mid-throughput sequencing by providing exceptional efficiency, output, and cost-effectiveness. It delivers performance and pricing comparable to previous higher-output systems while offering laboratories the speed and adaptability needed for a broad spectrum of genomic applications, including Whole Genome Sequencing, Single Cell, Spatial, Oncology, Rare Disease, and Metagenomics— all within a streamlined and user-friendly workflow.
Rare Disease Day Interview with Dr. Ashraf Dallol: NoorDx's Approach to Alpha Thalassemia Through MGI Technology
Rare Disease Day, celebrated annually on the last day of February, is a global event aiming to raise awareness about rare diseases and their impact on patients' lives. This year, we shed light on the rare condition alpha thalassemia, an inherited blood disorder caused by mutations in the alpha-globin gene cluster, affecting hemoglobin production and leading to severe anemia and other complications.
We invited Dr. Ashraf Dallol, the Senior Laboratory Director at NoorDx in Saudi Arabia, to share his vital work in the field of alpha thalassemia research in the MENA region, as well as his experience utilizing cutting-edge genomic technology from MGI to address the prevalent rare condition.
Delve into the conversation with Dr. Ashraf as follows??
World Cancer Day: Advancing Precision Cancer Care with OncoDNA & MGI
The theme of World Cancer Day 2025 is “United by Unique”. In the latest episode of the MGI podcast, we invite industry experts to share their insights on the evolving landscape of genomic medicine and multiple collaborative entities that unite in their mission to conquer cancers.
--Dr. Cheng Boon, an oncologist, and OncoDNA Medical Director, shares frontline clinical insights.
--Dr. Gareth Gerrard, a clinical scientist, discusses the challenges and opportunities in implementation.
--Filips Oleskovs, from MGI, provides a technology provider’s perspective on advancing accessibility.
Tune in to hear how genomics is shaping the future of cancer treatment and making personalized medicine a reality.
Future of Omics Interviews Series
In this episode, we hear from James Cavaggion, the Director of NutriPATH Pathology, who discussed their business regarding microbiomes and their plans to implement metagenomic sequencing as an extension of their current offerings. He shared his positive experiences collaborating with MGI and highlighted the appeal of the personalized laboratory automation solutions MGI provides.
Establish Partnership with Oncoclínicas&Co to Contribute to Genomic Innovation in Oncological Health
In February, MGI established a partnership with Oncoclínicas&Co, through OC Medicina de Precis?o, which comprises Genomics, Pathology and Big Data laboratories, to expand access to cutting-edge genomic tests and strengthen diagnostic capabilities in the field of oncology in Brazil.
Unlock the Full Potential of Targeted Sequencing by the ATOPlex Platform
The coverage from GenomeWeb leaks out exciting news: MGI's ATOPlex multiplex PCR-based library preparation platform for targeted sequencing applications will soon support library prep for its CycloneSEQ long-read sequencer!
With its ultra-high multiplex PCR technology, streamlined workflow, and ability to process up to 20,000 targets in a single reaction, ATOPlex offers a cost-effective, highly sensitive, and scalable approach to genetic analysis.
Compared with probe-based targeted enrichment,?an amplicon-based method,?such as MGI’s ATOPlex Platform,?has the advantages of low cost, low sample input requirements, ease of customization, and the ability to achieve higher sequencing depth.
New Sequencer Installation in Turkey – Nevagen’s DNBSEQ-T7 in Action!
We are honored to support NEVAGEN GENET?K HASTALIKLAR DE?ERLEND?RME MERKEZ? in their journey with the power of DNBSEQ-T7! Featuring exceptional speed, scalability, and cost efficiency, we believe the T7 sequencer will empower Nevagen’s laboratory to achieve groundbreaking results in genomics research and clinical applications. Congrats on the collaborative achievement with the Nevagen team, and a huge thank you to all the teammates who contributed to this collaboration, making this milestone possible! A special shoutout to Ozan S?nmez, BD manager from Nevagen, Mücahit MUCIK, Product & Application Manager from Nevagen, and Sefa Akdo?an, Sales Manager from Invitrotek for their dedication and key contributions in bringing this project to life.
New Distributor Partnership in Egypt
We are thrilled to announce our collaboration with Agitech in Egypt! This partnership will introduce advanced lab equipment to the Egyptian market. Together, we are committed to delivering cutting-edge laboratory solutions and exceptional service to our customers. Here’s to a successful partnership and a promising future ahead!
World Wetlands Day 2025: Protecting Wetlands for Our Common Future
On World Wetlands Day, we reflect again on how MGI's innovative sequencing technology supports mangrove conservation efforts in Thailand in collaboration with the National Omics Center (NOC) under the National Science and Technology Development Agency (NSTDA).
Thank you for reading! Catch us next month and follow us on LinkedIn, X, and YouTube for more of the latest content from MGI. To get more information, please visit the MGI website.
Warmest regards,
The “MGI Newsletter” Editorial Team